Table 4.

Summary of Adverse Events by Renal Function and Treatment Groups

	Number of Subjects (%)
	Normal Renal Function			Moderate RI
	CSL112 2 g	CSL112 6 g	Placebo	CSL112 2 g	CSL112 6 g	Placebo
	(n = 6)	(n = 6)	(n = 4)	(n = 6)	(n = 6)	(n = 4)
Any TEAE	3 (50.0)	5 (83.3)	2 (50.0)	1 (16.7)	3 (50.0)	0
Blood bilirubin increased	0	0	0	0	2 (33.3)	0
Headache	0	2 (33.3)	1 (25.0)	0	0	0
Serious AE	0	2 (33.3)	0	0	0	0
Procedure‐related AEs	1 (16.7)	2 (33.3)	1 (25.0)	1 (16.7)	0	0
Treatment‐related AEs	0	2 (33.3)	1 (25.0)	1 (16.7)	3 (50.0)	0

AE, adverse event; RI, renal impairment; TEAE, treatment‐emergent adverse event.